Top stories in gastroenterology: Entyvio superior to Humira, upadacitinib effective in ulcerative colitis induction

Among the top stories in gastroenterology last week were trial results that maintained that Entyvio conferred superior clinical remission and mucosal healing compared to Humira among patients with moderately to severely active ulcerative colitis and data that suggested that patients treated with upadacitinib for ulcerative colitis experienced better endoscopic and histologic outcomes, as well as better mucosal healing, than patients who received placebo.

Other highlights included a study that found etrasimod was effective in inducing endoscopic and histologic remission in patients with moderately to severely active ulcerative colitis, data that indicated that patients with Crohn’s disease who either lost or had inadequate response to therapy with Stelara were able to recapture that response by having their dosing interval cut in half and results from the GEMINI trial that suggested Entyvio had a suitable safety profile for the long-term treatment of inflammatory bowel disease.

Entyvio superior to Humira in moderate, severe ulcerative colitis

Entyvio conferred superior clinical remission and mucosal healing compared with Humira among patients with moderately to severely active ulcerative colitis, according to results of a phase 3b randomized trial presented at the Congress of the European Crohn’s and Colitis Organisation. Read more.

Upadacitinib effective in ulcerative colitis induction

Patients treated with upadacitinib for ulcerative colitis experienced better endoscopic and histologic outcomes as well as better mucosal healing compared with patients who received placebo, according to data presented at the Congress of the European Crohn’s and Colitis Organisation. Read more.

Etrasimod induces endoscopic, histologic improvement in ulcerative colitis

Etrasimod — an oral, selective sphingosine-1-phosphate receptor modulator — was effective in inducing endoscopic and histologic remission, as well as histological remission and mucosal healing in patients with moderately to severely active ulcerative colitis, according to study results presented at the Congress of the European Crohn’s and Colitis Organisation. Read more.

Optimization helps patients with Crohn’s recapture Stelara response

Patients with Crohn’s disease who either lost or had inadequate response to therapy with Stelara were able to recapture that response by having their dosing interval cut in half, according to data presented at the Congress of the European Crohn’s and Colitis Organisation. Read more.

GEMINI: Entyvio safe long-term for Crohn’s, ulcerative colitis

Final results from the GEMINI trial revealed that Entyvio had a suitable safety profile for long-term treatment of inflammatory bowel disease, according to data presented at the Congress of the European Crohn’s and Colitis Organisation. Read more.